Trials / Completed
CompletedNCT03663114
A Post-marketing Observational Study on Risk Factors for Hepatic Encephalopathy in Participants With Unresectable Hepatocellular Carcinoma
A Drug Use Investigation of LENVIMA 4 mg Capsules - A Post-marketing Observational Study on Risk Factors for Hepatic Encephalopathy in Patients With Unresectable Hepatocellular Carcinoma
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 713 (actual)
- Sponsor
- Eisai Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a post-marketing observational study of lenvatinib in participants with unresectable hepatocellular carcinoma. The primary objective of this study is assessment of risk factors for hepatic encephalopathy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lenvatinib | Lenvatinib capsule |
Timeline
- Start date
- 2018-07-02
- Primary completion
- 2020-02-20
- Completion
- 2020-02-20
- First posted
- 2018-09-10
- Last updated
- 2021-01-22
Locations
2 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT03663114. Inclusion in this directory is not an endorsement.